2019
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkage
2017
B Cell Biology
Sadanand S, Tomayko M. B Cell Biology. 2017, 97-119. DOI: 10.1007/978-3-319-29785-9_7.ChaptersB cell biologyCell biologyB cellsImmune responseEffector functionsB cell-T cell interactionsCell-T cell interactionsB cell developmentCurrent therapeutic mechanismsRegulatory B cellsB-cell depletionB cell responsesAdaptive immune responsesMemory B cellsGerminal center responseEstablishment of toleranceCell developmentCentral playerProtective immunityCell depletionDurable immunityAntigenic targetsAntibody isotypesPlasma cellsTherapeutic mechanism